HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CIR meets with Crawford

This article was originally published in The Rose Sheet

Executive Summary

Cosmetic Ingredient Review provides FDA a list of 132 ingredients with insufficient safety data during its first meeting with FDA Acting Commissioner Lester Crawford, CIR Director Alan Andersen, PhD, reports during panel's June 13-14 meeting in Washington, D.C. Sitdown, which occurred April 25, is part of a new credibility action plan developed by the Cosmetic, Toiletry and Fragrance Association (1"The Rose Sheet" March 14, 2005, p. 3). CIR is seeking to encourage FDA to "implement its available regulatory authority to require warning labels or suggest to companies that warning labels may be required...as a way to encourage the industry to provide the data to fill the...gaps that the panel has identified," Anderson notes...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts